On July 10, 2025, Suzhou Linaxin Biotechnology Co., Ltd. and Zhejiang Qianjifang Pharmaceutical Technology Co., Ltd. officially signed a strategic cooperation agreement in Hangzhou. The two parties will focus on; No cancer in the world, early screening and treatment; Deepen cooperation in health projects, jointly build a full cycle service system for cancer prevention and control, and inject new momentum into the cause of national health.

Both parties will carry out collaborative innovation in three major areas:

1. Global coverage of early screening network: Relying on Linaxin's independently developed digestive cancer early screening technology, and in conjunction with Qianjifang's resource advantages in medical channels, we promote highly sensitive and convenient early screening services to hospitals, physical examination centers, and community residents, and push the cancer prevention and control checkpoint forward;

2. Closed loop management of positive cases: For screening positive populations, Qianjifang provides clinically validated targeted intervention products, combined with Linaxin's post test health management platform, to achieve precise services throughout the entire process of "screening diagnosis intervention follow-up";

3. Deep implementation of health mission: Both sides will jointly advocate the public welfare concept of "promoting with love, supporting with medicine, witnessing with effectiveness, and providing caring services", and enhance public awareness of cancer prevention through science popularization education, free medical screening and other activities.

Dr. Tan Shengwei, Chairman of Suzhou Linaxin Biotechnology Co., Ltd., said at the signing ceremony, "This cooperation is a complementary advantage between technology enterprises and pharmaceutical enterprises. Linaxin will leverage its technological leadership in the field of molecular diagnostics to make early screening technology more accessible and universal, and help realize the social value of 'discovering one case of early cancer, saving one life, and creating a happy family'

The person in charge of Zhejiang Qianjifang Pharmaceutical Technology Co., Ltd. emphasized, "Qianjifang has always been committed to the modernization and innovation of traditional Chinese medicine. With the cooperation of Linaxin, we will use scientifically validated products as the starting point to provide personalized intervention plans for high-risk populations, and jointly build a healthy ecological chain from prevention to rehabilitation.

This strategic cooperation marks the upgrade of China's cancer prevention and control model from "single point treatment" to "full cycle management". Both parties plan to build 500 early screening service outlets in the Yangtze River Delta region within three years, train over a thousand professional health managers, and benefit millions of families. Contribute to the strategic goal of "Healthy China 2030" through technological sinking and model innovation.

In the future, Suzhou Linaxin and Zhejiang Qianjifang will continue to deepen their cooperation in industry, academia, and research, safeguard life and health through technological innovation, and fulfill their mission of "cancer free the world" with practical actions, working together to write a new chapter in cancer prevention and control.